百利天恒2025年净利预亏11亿元，同比转亏

Core Viewpoint - The company, Baili Tianheng, anticipates a significant decline in net profit for 2025, projecting a loss of approximately 1.1 billion yuan, which represents a year-on-year decrease of about 129.67% [1] Financial Performance - The projected net profit for 2025 is around -1.1 billion yuan, indicating a substantial loss compared to the previous year [1] - The decrease in revenue is primarily attributed to the recognition of a larger intellectual property income from a previous upfront payment of 800 million USD from BMS in the prior year, compared to the milestone payment of 250 million USD received during the current reporting period [1] Research and Development - The company is increasing its R&D investment significantly to accelerate the development of its product pipeline and maintain its competitive edge [1] - The collaboration with Bristol-Myers Squibb (BMS) on the drug iza-bren is progressing well, with the achievement of a milestone in the global II/III phase key registration clinical trial, leading to the receipt of a milestone payment [1]